Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.665
-0.205 (-5.30%)
Mar 20, 2026, 3:06 PM EDT - Market open
Iovance Biotherapeutics Analyst Ratings
Total Analysts
10
Consensus Rating
Buy
Price Target
$9.11
Upside
+148.57%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +9.14% | Mar 5, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +36.43% | Mar 3, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +200.14% | Feb 25, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +36.43% | Feb 25, 2026 |
| Barclays | Barclays | Buy Maintains $9 → $10 | Buy | Maintains | $9 → $10 | +172.85% | Dec 17, 2025 |
| Barclays | Barclays | Buy Maintains $4 → $9 | Buy | Maintains | $4 → $9 | +145.57% | Nov 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +363.85% | Nov 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $9 | Strong Buy | Maintains | $20 → $9 | +145.57% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +445.70% | Aug 19, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $14 | Buy | Maintains | $18 → $14 | +281.99% | Aug 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | +445.70% | Aug 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +582.13% | Jul 23, 2025 |
| UBS | UBS | Strong Buy → Hold Downgrades $17 → $2 | Strong Buy → Hold | Downgrades | $17 → $2 | -45.43% | May 16, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +118.28% | May 12, 2025 |
| Mizuho | Mizuho | Buy Maintains $30 → $10 | Buy | Maintains | $30 → $10 | +172.85% | May 12, 2025 |
| Barclays | Barclays | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +9.14% | May 12, 2025 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.